GE HealthCare has announced the release of MyBreastAI Suite, a new AI-powered platform for mammography, designed to aid clinicians in detecting breast cancer. This platform integrates AI applications from iCAD, focusing on breast density assessment and enhancing the efficiency of mammography workflows. Addressing the challenges posed by the global rise in breast cancer cases, MyBreastAI Suite aims to streamline breast cancer detection.…
AI-enabled cancer diagnostics company Lunit, recently announced a financial boost with a $150M investment from its shareholders. The South Korean company, listed on the KOSDAQ, plans to invest these funds into new product development and strengthen its foothold in Western markets. The recent funding milestone is complemented by Lunit’s achievement in securing its third 510(k) clearance from the U.S. Food and Drug…
Mammogen, a precision diagnostics company, has recently completed the Clinical Laboratory Improvement Amendments (CLIA) validation for its genTRU-breast assay. This blood test is designed for the early detection of breast cancer and marks a significant step in the field of women’s health diagnostics. The foundation of Mammogen was inspired by a personal experience: the founder’s sister’s best friend, Katy, was diagnosed with…
Andira Pharmaceuticals, a Canadian health science firm, has recently announced significant progress in the treatment of breast cancer with its pioneering formula, XOXO4. The company’s flagship oncology candidate, XOXO4, has demonstrated remarkable efficacy in regressing human breast cancer tumors. Conducted at the University of British Columbia, the study highlighted that XOXO4, a cannabinoid formula applied topically, outperformed all eight FDA-approved breast cancer-specific…
Delphinus Medical Technologies, a pioneer in dense breast medical imaging, has secured $12M in growth capital from Trinity Capital. The funding will accelerate the adoption of their SoftVue 3D Whole Breast Tomography System, which enhances early breast cancer detection. The SoftVue system gained FDA approval in 2021 as an adjunct to digital mammography for screening asymptomatic women with dense breast tissue. Addressing…
Novartis has unveiled significant findings from the Phase III NATALEE trial, demonstrating that Kisqali (ribociclib) can effectively reduce the risk of cancer recurrence by 25.2% in patients with early breast cancer. The trial results were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and showcased a consistent and clinically meaningful benefit of Kisqali across a broad range of…
Gabbi, the risk assessment and care navigation company, today announced it has raised a round of $4.4M to help tackle its mission of ensuring breast cancer is detected at the earliest possible stages when it is a treatable, survivable disease. Bread and Butter Ventures led the round which also saw participation from Female Founders Fund, WR Hambrecht, Phoenix Rising, Claridge Ventures Advisors VC, Coyote…
Following a year in which Vara expanded into international markets like Greece and Mexico, the deeptech startup today announces that it has raised a further €4.5 million to continue international expansion. The extension, which takes the total Series A funding raised to €11 million, was led by VI Partners and included impact investor, EQT Foundation, as well as the family office behind one…
